Gene Expression Profile Associated with Response to Doxorubicin-Based Therapy in Breast Cancer
Purpose: This study was designed to identify genes that could predict response to doxorubicin-based primary chemotherapy in breast cancer patients. Experimental Design: Biopsy samples were obtained before primary treatment with doxorubicin and cyclophosphamide. RNA was extracted and amplified and ge...
Saved in:
Published in: | Clinical cancer research Vol. 11; no. 20; pp. 7434 - 7443 |
---|---|
Main Authors: | , , , , , , , , , , , , , , , , , , |
Format: | Journal Article |
Language: | English |
Published: |
Philadelphia, PA
American Association for Cancer Research
15-10-2005
|
Subjects: | |
Online Access: | Get full text |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Summary: | Purpose: This study was designed to identify genes that could predict response to doxorubicin-based primary chemotherapy in breast
cancer patients.
Experimental Design: Biopsy samples were obtained before primary treatment with doxorubicin and cyclophosphamide. RNA was extracted and amplified
and gene expression was analyzed using cDNA microarrays.
Results: Response to chemotherapy was evaluated in 51 patients, and based on Response Evaluation Criteria in Solid Tumors guidelines,
42 patients, who presented at least a partial response (≥30% reduction in tumor dimension), were classified as responsive.
Gene profile of samples, divided into training set ( n = 38) and independent validation set ( n = 13), were at first analyzed against a cDNA microarray platform containing 692 genes. Unsupervised clustering could not
separate responders from nonresponders. A classifier was identified comprising EMILIN1, FAM14B , and PBEF , which however could not correctly classify samples included in the validation set. Our next step was to analyze gene profile
in a more comprehensive cDNA microarray platform, containing 4,608 open reading frame expressed sequence tags. Seven samples
of the initial training set (all responder patients) could not be analyzed. Unsupervised clustering could correctly group
all the resistant samples as well as at least 85% of the sensitive samples. Additionally, a classifier, including PRSS11, MTSS1 , and CLPTM1 , could correctly distinguish 95.4% of the 44 samples analyzed, with only two misclassifications, one sensitive sample and
one resistant tumor. The robustness of this classifier is 2.5 greater than the first one.
Conclusion: A trio of genes might potentially distinguish doxorubicin-responsive from nonresponsive tumors, but further validation by
a larger number of samples is still needed. |
---|---|
Bibliography: | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 |
ISSN: | 1078-0432 1557-3265 |
DOI: | 10.1158/1078-0432.CCR-04-0548 |